Preclinical Toxicity Testing

The National Institutes of Health, Office of Logistics and Acquisition Operations is seeking preclinical toxicity testing services for six novel drugs to support drug discovery projects within the Laboratory of Bioorganic Chemistry. The testing will focus on solubility and bioavailability assessments and must maintain strict consistency with all previous testing protocols established under prior contracts to ensure data integrity for longitudinal comparison and publication purposes. This is a sole-source procurement under FAR Part 6.302-1, with the primary evaluation criterion being the contractor's ability to maintain protocol consistency with established methodologies. While the government intends to award to the current contractor, small businesses including 8(a) certified, service-disabled veteran-owned, HUBZone, small disadvantaged, veteran-owned, and women-owned small business entities may submit written capability statements to compete at the government's sole discretion. Capability statements must be submitted via email to david.shen@nih.gov no later than 6:00 a.m. EDT on May 1, 2026, with award anticipated approximately five days after notice publication.

This procurement carries no set-aside designation and is structured as a Firm-Fixed-Price Purchase Order. The incumbent contractor is Jai Research Foundation, which has performed the work under two prior contracts (75N94021P00704 and 75N94020P00891) and is the identified source for this continuation based on the critical requirement for protocol consistency. No specific contract value or budget range is disclosed in the notice. The work involves testing of six novel drugs and is classified under NAICS 541714 (Research and Development in Biotechnology) and PSC Q301 (Reference Laboratory Testing), with the government emphasizing that any deviation from established protocols could result in loss of meaningful data and costly recalibration of historical datasets.